BC
NTLA icon

Bayforest Capital’s Intellia Therapeutics NTLA Stock Holding History

Bayforest Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Buy
7,403
+1,033
+16% +$14.5K 0.12% 350
2026
Q1 		$81.7K Buy
+6,370
New +$81.1K 0.09% 423
2025
Q4 		– Sell
-262
Closed -$4.53K – 903
2025
Q3 		$4.53K Buy
+262
New +$3.23K ﹤0.01% 698
2025
Q1 		– Sell
-2,496
Closed -$29.1K – 846
2024
Q4 		$29.1K Buy
+2,496
New +$39K 0.04% 540

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Bayforest Capital's NTLA Position: Q2 2026 in Review

Bayforest Capital increased its Intellia Therapeutics (NTLA) stake by 16% in Q2 2026, buying an estimated $14.5K and bringing the position to 7,403 shares worth $125K. The position accounts for 0.12% of the portfolio, ranked #350.

Bayforest Capital first reported a position in NTLA in Q4 2024 and has held it in 4 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Bayforest Capital held 7,403 shares of Intellia Therapeutics worth $125K as of Q2 2026.
  • Bayforest Capital bought 1,033 Intellia Therapeutics shares in Q2 2026, an estimated $14.5K.
  • Intellia Therapeutics made up 0.12% of Bayforest Capital's portfolio in Q2 2026, its #350 holding.
  • Bayforest Capital first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.